Drug Trial Radar · NCT06208306
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
669
Actual
Start
Jan 11, 2024
Primary completion
Sep 10, 2026
Study completion Sep 10, 2026
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- Collaborators
- Regeneron Pharmaceuticals
- First posted
- Jan 17, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a parallel, double blind, Phase 3, 2-arm study that is designed to provide additional safety information, assess the durability of treatment response, and provide additional PK and immunogenicity assessments. The primary purpose of this study is to evaluate safety and tolerability of both itepekimab SC Q2W or itepekimab SC Q4W in participants with COPD having completed the treatment period of the clinical studies EFC16750 or EFC16819. A secondary purpose of this study is to provide efficacy outcomes beyond the treatment period of the parent trials EFC16750 and EFC16819. Study details include: * The study duration will be up to 72 weeks * The treatment duration will be up to 52 weeks * A follow-up period of 20 weeks will be conducted * The number of on-site visits will be 7 and the number of phone contacts will be 5
Conditions
- Chronic Obstructive Pulmonary Disease
Interventions
Itepekimab (SAR440340)Drug
Pharmaceutical form:solution for injection in pre-filled syringe Route of administration:subcutaneous
PlaceboDrug
Pharmaceutical form:solution for injection in pre-filled syringe Route of administration:subcutaneous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent AEs, AESIs, SAEs, and AEs leading to permanent treatment discontinuationTime frame: Baseline up to Week 72
Locations
223 sites in 32 countries. Site status is shown where the registry gives one.
Chandler Clinical Research Trials- Site Number : 8401034
Chandler, Arizona
Noble Clinical Research Site Number : 8401182
Tucson, Arizona
Tucson Clinical Research Institute- Site Number : 8401431
Tucson, Arizona
IMAX Clinical Trials- Site Number : 8401419
La Palma, California
Antelope Valley Clinical Trials Site Number : 8401003
Lancaster, California
Downtown L.A. Research Center- Site Number : 8401027
Los Angeles, California
Allianz Research Institute CO Site Number : 8402061
Aurora, Colorado
Alpine Clinical Research Center - Boulder - 47th Street- Site Number : 8401180
Boulder, Colorado
Helix Biomedics- Site Number : 8402049
Boynton Beach, Florida
Beautiful Minds Clinical Research Center Site Number : 8401201
Cutler Bay, Florida
Omega Research Consultants - Debary - North Charles Richard Beall Boulevard- Site Number : 8402031
DeBary, Florida
Science Connections, LLC Site Number : 8402045
Doral, Florida
Direct Helpers Research Center- Site Number : 8402065
Hialeah, Florida
Premier Medical Associates Site Number : 8401388
Lady Lake, Florida
Advanced Pulmonary Research Institute Site Number : 8402018
Loxahatchee Groves, Florida
Finlay Medical Research- Site Number : 8402007
Miami, Florida
Elite Clinical Research - Miami- Site Number : 8402009
Miami, Florida
DL Research Solutions- Site Number : 8401033
Miami, Florida
My Community Research Center Site Number : 8402060
Miami, Florida
Phoenix Medical Research - Miami - 24th Street- Site Number : 8402019
Miami, Florida
Research Institute of South Florida- Site Number : 8401006
Miami, Florida
Reed Medical Research Site Number : 8401032
Miami, Florida
High Quality Research Site Number : 8401406
Miami, Florida
Deluxe Health Center Site Number : 8401188
Miami Lakes, Florida
Renstar Medical Research - Ocala - Northeast 1st Avenue- Site Number : 8402015
Ocala, Florida
Heuer M.D. Research- Site Number : 8402016
Orlando, Florida
Florida Institute for Clinical Research Site Number : 8401013
Orlando, Florida
Oviedo Medical Research Site Number : 8402026
Oviedo, Florida
Innovation Medical Research Center - Palmetto Bay- Site Number : 8402067
Palmetto Bay, Florida
Pines Care Research Center- Site Number : 8402056
Pembroke Pines, Florida
Tellabio International Research Services Site Number : 8401411
Pembroke Pines, Florida
Clinical Research of West Florida - Tampa - North Howard Avenue- Site Number : 8402008
Tampa, Florida
Appalachian Clinical Research Site Number : 8400024
Calhoun, Georgia
Private Practice - Dr. David Kavtaradze- Site Number : 8401029
Cordele, Georgia
Alpha Clinical Research Group - Dunwoody- Site Number : 8401190
Dunwoody, Georgia
Covenant Pulmonary Critical Care Site Number : 8401183
East Point, Georgia
OSF Saint Fracis Medical Center- Site Number : 8402024
Peoria, Illinois
Benchmark Research - Covington- Site Number : 8401193
Covington, Louisiana
Care Access - Shreveport- Site Number : 8402047
Shreveport, Louisiana
Private Practice - Dr. Paul Shapero- Site Number : 8401016
Bangor, Maine
Showing 40 of 223 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.